Exogenus Therapeutics

About:

Exogenus Therapeutics develops cellular based therapies applied to regenerative medicine for skin lesions treatment.

Website: http://www.exogenustherapeutics.com

Twitter/X: exogenust

Top Investors: Caixa Capital, EASME - EU Executive Agency for SMEs, ChangePartners

Description:

Exogenus Therapeutics is engineering cell biology for innovative therapeutic solutions. Exo-T is a biotechnology company dedicated to the pre-clinical and clinical development of innovative cellular-based therapies applied to regenerative medicine, specifically for the skin lesions treatment. The company is presently developing its first product, Exo-Wound, for the treatment of chronic wounds. The project that led to the creation of the company (Nanoinspire) participated in COHiTEC 2014 program and is the result of the research developed in collaboration with Crioestaminal SA, Biocant, and Centre for Neurosciences and Cellular Biology of Coimbra University.

Total Funding Amount:

850000 EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cantanhede, Coimbra, Portugal

Founded Date:

2015-06-02

Contact Email:

team(AT)exogenus-t.com

Founders:

Joana Simões Correia, Luisa Marques, Ricardo Neves

Number of Employees:

1-10

Last Funding Date:

2016-12-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai